Molecular Editing in Drug Discovery: Making Peripheral and Skeletal Changes
Drug discovery often begins with high-throughput screening of large libraries to identify potential hits.
April 1, 2025
by Suzanne Elvidge
How AI Can Drive Drug Discovery
The use of artificial intelligence (AI) is growing, from banking and biodiversity to travel and transport. One of the areas where its presence is significant is healthcare.
November 27, 2024
by Suzanne Elvidge
Artificial Intelligence for Drug Development
Artificial Intelligence (AI) is making a significant impact in the pharmaceutical industry, revolutionizing various aspects of drug discovery, development, and healthcare.
July 31, 2023
by David Orchard-Webb
Avantor Inaugurates Expanded Singapore Hub
On July 11, 2023,Avantor, Inc. inaugurated its expanded Singapore Hub which includes newly added cGMP manufacturing and a world class quality control laboratory.
July 12, 2023
by PharmaSources
X-Chem and Excelra's GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets
A new collaboration between data science and analytics leader, Excelra, and artificial intelligence pioneer X-Chem will accelerate preclinical drug discovery and aid scientists to find new drug candidates for currently hard-to-drug targets.
February 11, 2022
by prnasia
XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform
Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company...
January 19, 2022
by prnasia
SMi's 5th Annual 3D Cell Culture Conference
3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery, from improved clinical translation and predictivity, to patient safety and sustainability.
January 19, 2022
by WorldPharmaNews
Charles River, Valo Enter AI-enabled Drug Discovery Pact
Multiyear partnership will leverage Valo’s Opal Computational Platform to accelerate drug discovery and development.
January 19, 2022
by contractpharma
Ono Pharma expands drug discovery collaboration with Neurimmune AG
The collaboration focusses on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform...
January 18, 2022
by ExpressPharma
Piramal to create screening facility to boost in-vitro biology capabilities
The move is expected to bring added value to customers by coupling biology services with existing chemistry capabilities.
January 14, 2022
by CPhIonline
Finding a new purpose for old drugs: Researchers have found promising drugs for COVID-19
Treatment options for COVID-19 remain limited. Researchers at the University of Helsinki and the University of Eastern Finland first searched for suitable drug targets and repurposable drugs for these...
November 5, 2021
by WorldPharmaNews
Alchemab completes £60m Series A funding to advance novel antibody platform
Cambridge, UK-based Alchemab Therapeutics has raised £60m ($82m) in a Series A funding round, in a bid to advance its target-agnostic drug discovery platform.
April 16, 2021
by pharmatimes